Published in Virchows Arch on June 24, 2004
Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol (2011) 2.38
Proficiency testing of immunohistochemical biomarker assays in breast cancer. Virchows Arch (2008) 1.38
Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. Breast Cancer Res (2014) 1.20
Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: a cohort study. Breast Cancer Res (2011) 1.08
SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases. BMC Cancer (2013) 0.95
Implementation of External Quality Assurance Trials for Immunohistochemically Determined Breast Cancer Biomarkers in Germany. Breast Care (Basel) (2008) 0.94
Progranulin as a prognostic biomarker for breast cancer recurrence in patients who had hormone receptor-positive tumors: a cohort study. PLoS One (2012) 0.87
[Interlaboratory trials for quality assurance of breast cancer biomarkers in Germany]. Pathologe (2008) 0.84
Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience. Indian J Med Paediatr Oncol (2015) 0.83
Study assessing the quality of quantification of estrogen receptor protein expression by immunohistochemistry and gene expression in breast cancer. Patholog Res Int (2014) 0.76
Quantification of Estrogen Receptor-Alpha Expression in Human Breast Carcinomas With a Miniaturized, Low-Cost Digital Microscope: A Comparison with a High-End Whole Slide-Scanner. PLoS One (2015) 0.75
The analytical validation of the Oncotype DX Recurrence Score assay. Ecancermedicalscience (2016) 0.75
DNA methylation profiling to assess pathogenicity of BRCA1 unclassified variants in breast cancer. Epigenetics (2015) 0.75
Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet (1998) 22.64
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol (1999) 11.18
Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol (2000) 2.35
Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J Clin Pathol (2000) 2.34
High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases. Histopathology (2000) 2.06
Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC. J Clin Pathol (2000) 1.81
Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assurance. Eur J Cancer (1998) 1.67
Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol (2000) 1.62
Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories. Virchows Arch (2002) 1.12
Estrogen receptor analysis in primary breast tumors by ligand-binding assay, immunocytochemical assay, and northern blot: a comparison. Breast Cancer Res Treat (2001) 0.98
Comparison of enzyme immunoassay and immunohistochemical measurements of estrogen and progesterone receptors in breast cancer patients. Appl Immunohistochem Mol Morphol (2001) 0.96
Immunohistochemical expression of hormone receptors in invasive breast carcinoma: correlation of results of H-score with pathological parameters. Pathology (2001) 0.95
Oestrogen and progesterone receptors in breast cancer: past, present and future. Histopathology (2001) 0.89
The effect of fixation and processing on the sensitivity of oestrogen receptor assay by immunohistochemistry in breast carcinoma. J Clin Pathol (2002) 0.80
Detection of the oestrogen receptor (ER). immunohistochemical versus cytosol measurements. Eur J Cancer (2000) 0.76
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology (1991) 30.87
Ensembl 2009. Nucleic Acids Res (2008) 25.38
Ensembl 2008. Nucleic Acids Res (2007) 20.67
Ensembl 2007. Nucleic Acids Res (2006) 20.10
Reduction of breast cancer mortality through mass screening with modern mammography. First results of the Nijmegen project, 1975-1981. Lancet (1984) 10.22
A prognostic index in primary breast cancer. Br J Cancer (1982) 7.35
The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat (1992) 6.51
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Mortality of employees of the United Kingdom Atomic Energy Authority, 1946-1979. Br Med J (Clin Res Ed) (1985) 5.48
A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature (1991) 5.13
Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene (2006) 4.85
The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation. Nat Genet (1993) 4.57
Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest (1997) 4.31
Candida dubliniensis: characteristics and identification. J Clin Microbiol (1998) 4.23
Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med (1988) 4.06
Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer (1985) 3.60
Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol (1997) 3.60
Widespread geographic distribution of oral Candida dubliniensis strains in human immunodeficiency virus-infected individuals. J Clin Microbiol (1997) 3.54
Simple, inexpensive, reliable method for differentiation of Candida dubliniensis from Candida albicans. J Clin Microbiol (1998) 3.44
Purification and cloning of interferon-stimulated gene factor 2 (ISGF2): ISGF2 (IRF-1) can bind to the promoters of both beta interferon- and interferon-stimulated genes but is not a primary transcriptional activator of either. Mol Cell Biol (1990) 3.31
Isolation of human NK cells by density gradient centrifugation. J Immunol Methods (1980) 3.30
Confirmation of a prognostic index in primary breast cancer. Br J Cancer (1987) 3.29
The role of chloroplasts and microsomal fractions in polar-lipid synthesis from [1-14C]acetate by cell-free preparations from spinach (Spinacia oleracea) leaves. Biochem J (1980) 3.26
Altered cellular mRNA levels in human cytomegalovirus-infected fibroblasts: viral block to the accumulation of antiviral mRNAs. J Virol (2001) 3.22
A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene (2006) 3.21
Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol (2003) 3.14
Distribution of epithelial membrane antigen in normal and neoplastic tissues and it value in diagnostic tumor pathology. Cancer (1981) 3.07
Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet (1998) 3.06
Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer (2004) 3.03
Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol (1994) 2.92
The current detectability of breast cancer in a mammographic screening program. A review of the previous mammograms of interval and screen-detected cancers. Cancer (1993) 2.88
Oligonucleotide fingerprinting of isolates of Candida species other than C. albicans and of atypical Candida species from human immunodeficiency virus-positive and AIDS patients. J Clin Microbiol (1993) 2.87
Neuroendocrine differentiation in Ewing's sarcomas and primitive neuroectodermal tumors revealed by reverse transcriptase-polymerase chain reaction of chromogranin mRNA. Diagn Mol Pathol (1998) 2.86
Factors influencing local recurrence after excision and radiotherapy for primary breast cancer. Br J Surg (1989) 2.84
European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition--summary document. Ann Oncol (2007) 2.84
Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology (1992) 2.75
Synergistic interaction between interferon-alpha and interferon-gamma through induced synthesis of one subunit of the transcription factor ISGF3. EMBO J (1990) 2.75
Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol (2008) 2.73
Overlapping elements in the guanylate-binding protein gene promoter mediate transcriptional induction by alpha and gamma interferons. Mol Cell Biol (1991) 2.71
Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol (2000) 2.68
Ductal carcinoma in-situ of the breast; second EORTC consensus meeting. Eur J Cancer (1992) 2.67
Damage to type II collagen in aging and osteoarthritis starts at the articular surface, originates around chondrocytes, and extends into the cartilage with progressive degeneration. J Clin Invest (1995) 2.67
[The treatment of ductal carcinoma in situ (DCIS) of the breast]. Ned Tijdschr Geneeskd (2003) 2.67
On the control of long-chain-fatty acid synthesis in isolated intact spinach (Spinacia oleracea) chloroplasts. Biochem J (1979) 2.56
Relationship of oestrogen-receptor status to survival in breast cancer. Lancet (1979) 2.55
Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol (1996) 2.53
Molecular epidemiology of tuberculosis in London 1995-7 showing low rate of active transmission. Thorax (2002) 2.53
Oestrogen receptor expression in the normal and pre-cancerous breast. J Pathol (1999) 2.52
Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages. J Immunol (1987) 2.52
Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol (2001) 2.51
The use of antisera to epithelial membrane antigen in detecting micrometastases in histological sections. Br J Cancer (1980) 2.50
Relationship between primary breast tumor receptor status and patient survival. Cancer (1980) 2.49
The UK colorectal cancer screening pilot: results of the second round of screening in England. Br J Cancer (2007) 2.48
Histoprognostic grade in BRCA1-associated breast cancer. Lancet (1995) 2.47
Extracorporeal shock wave therapy in the treatment of lateral epicondylitis : a randomized multicenter trial. J Bone Joint Surg Am (2002) 2.45
Reduction in the number of sentinel lymph node procedures by preoperative ultrasonography of the axilla in breast cancer. Eur J Cancer (2003) 2.40
Isolation of dermatan sulfate proteoglycans from mature bovine articular cartilages. J Biol Chem (1985) 2.39
[Dutch Institute for Healthcare Improvement guideline, "Treatment of breast cancer"]. Ned Tijdschr Geneeskd (2002) 2.39
The cancer research campaign (King's/Cambridge trial for early breast cancer: clinico-pathological aspects. Br J Cancer (1982) 2.39
Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. Br J Surg (2004) 2.36
Neuroendocrine differentiation and prognosis in breast adenocarcinoma. Histopathology (2002) 2.35
A simplified method of detection of clonal rearrangements of the T-cell receptor-gamma chain gene. Diagn Mol Pathol (1992) 2.33
WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type. Oncogene (2001) 2.32
Proteoglycans from bovine nasal cartilage. Properties of a soluble form of link protein. J Biol Chem (1979) 2.32
Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am J Pathol (1999) 2.32
Efficacy of topical treatments for cutaneous warts: a meta-analysis and pooled analysis of randomized controlled trials. Br J Dermatol (2011) 2.29
Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol (2001) 2.29
Are neostriatal dopamine receptors co-localized? Trends Neurosci (1993) 2.28
Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol (2001) 2.28
Mechanisms of DNA double strand break repair and chromosome aberration formation. Cytogenet Genome Res (2004) 2.26
Gynecomastia in type-1 neurofibromatosis with features of pseudoangiomatous stromal hyperplasia with giant cells. Report of two cases. Virchows Arch (2001) 2.25
Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci U S A (1995) 2.25
Malignant histiocytosis of the intestine: a T-cell lymphoma. Lancet (1985) 2.25
Upper extremity weight-training modifications for the injured athlete. A clinical perspective. Am J Sports Med (1998) 2.24
Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa. Science (1988) 2.24
Clonality and X-inactivation patterns in hematopoietic cell populations detected by the highly informative M27 beta DNA probe. Blood (1994) 2.24
Alpha-smooth muscle actin, a differentiation marker of smooth muscle cells, is present in microfilamentous bundles of pericytes. J Histochem Cytochem (1989) 2.23
Identification and expression of cephamycinase bla(CMY) genes in Escherichia coli and Salmonella isolates from food animals and ground meat. Antimicrob Agents Chemother (2001) 2.22
Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J Pathol (1999) 2.22
A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Hum Pathol (1995) 2.20
Observation unit treatment of heart failure with nesiritide: results from the proaction trial. J Emerg Med (2005) 2.19
Population needs assessment and knee replacement surgery. Rheumatology (Oxford) (2003) 2.18
Local recurrence after breast-conserving surgery and radiotherapy. Frequency, time course, and prognosis. Cancer (1989) 2.18
Small cell neuroendocrine carcinoma of the breast: a report of three cases and review of the literature. J Clin Pathol (2005) 2.18
A case-control study of gastric cancer and diet in Italy. Int J Cancer (1989) 2.17
A novel mitochondrial septin-like protein, ARTS, mediates apoptosis dependent on its P-loop motif. Nat Cell Biol (2000) 2.17
Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity (2000) 2.17
Sequence and analysis of chromosome 3 of the plant Arabidopsis thaliana. Nature (2000) 2.17
Sentinel node biopsy for breast cancer may have little to offer four-node-samplers. results of a prospective comparison study. Eur J Cancer (2001) 2.16
Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol (1997) 2.15